Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Capital Expenditures: 2011-2025

Historic Capital Expenditures for Adma Biologics (ADMA) over the last 10 years, with Sep 2025 value amounting to $14.4 million.

  • Adma Biologics' Capital Expenditures rose 1260.61% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.2 million, marking a year-over-year increase of 263.76%. This contributed to the annual value of $8.2 million for FY2024, which is 72.42% up from last year.
  • Per Adma Biologics' latest filing, its Capital Expenditures stood at $14.4 million for Q3 2025, which was up 493.23% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Capital Expenditures ranged from a high of $14.4 million in Q3 2025 and a low of $757,000 during Q3 2023.
  • Its 3-year average for Capital Expenditures is $3.1 million, with a median of $2.1 million in 2024.
  • In the last 5 years, Adma Biologics' Capital Expenditures tumbled by 77.87% in 2023 and then skyrocketed by 1,260.61% in 2025.
  • Quarterly analysis of 5 years shows Adma Biologics' Capital Expenditures stood at $3.7 million in 2021, then rose by 1.98% to $3.7 million in 2022, then crashed by 68.07% to $1.2 million in 2023, then soared by 130.33% to $2.8 million in 2024, then soared by 1,260.61% to $14.4 million in 2025.
  • Its Capital Expenditures was $14.4 million in Q3 2025, compared to $2.4 million in Q2 2025 and $4.7 million in Q1 2025.